Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Tumor-shed antigen CA125 blocks complement-mediated killing via suppression of C1q-antibody binding.

Kline JB, Fernando S, Ross EN, Grasso L, Nicolaides NC.

Eur J Immunol. 2018 Nov;48(11):1872-1882. doi: 10.1002/eji.201847707. Epub 2018 Oct 19.

PMID:
30144039
2.

CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients.

Nicolaides NC, Schweizer C, Somers EB, Wang W, Fernando S, Ross EN, Grasso L, Hassan R, Kline JB.

Cancer Biol Ther. 2018 Jul 3;19(7):622-630. doi: 10.1080/15384047.2018.1449614. Epub 2018 Apr 25.

3.

FCGR2A and FCGR3A Genotypes Correlate with Farletuzumab Response in Patients with First-Relapsed Ovarian Cancer Exhibiting Low CA125.

Wang W, Somers EB, Ross EN, Kline JB, O'Shannessy DJ, Schweizer C, Weil S, Grasso L, Nicolaides NC.

Cytogenet Genome Res. 2017;152(4):169-179. doi: 10.1159/000481213. Epub 2017 Oct 18.

PMID:
29041009
4.

CA125 effects on humoral immunosuppression.

Kline JB, Nicolaides NC.

Aging (Albany NY). 2017 Oct 3;9(10):2010-2011. doi: 10.18632/aging.101301. No abstract available.

5.

Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-γ receptor engagement.

Kline JB, Kennedy RP, Albone E, Chao Q, Fernando S, McDonough JM, Rybinski K, Wang W, Somers EB, Schweizer C, Grasso L, Nicolaides NC.

Oncotarget. 2017 Jul 7;8(32):52045-52060. doi: 10.18632/oncotarget.19090. eCollection 2017 Aug 8.

6.

Site-Specific Conjugation to Native and Engineered Lysines in Human Immunoglobulins by Microbial Transglutaminase.

Spidel JL, Vaessen B, Albone EF, Cheng X, Verdi A, Kline JB.

Bioconjug Chem. 2017 Sep 20;28(9):2471-2484. doi: 10.1021/acs.bioconjchem.7b00439. Epub 2017 Sep 6.

PMID:
28820579
7.

Engineering humanized antibody framework sequences for optimal site-specific conjugation of cytotoxins.

Spidel JL, Albone EF, Cheng X, Vaessen B, Jacob S, Milinichik AZ, Verdi A, Kline JB, Grasso L.

MAbs. 2017 Aug/Sep;9(6):907-915. doi: 10.1080/19420862.2017.1330734. Epub 2017 May 25.

8.

Generation of therapeutic immunoconjugates via Residue-Specific Conjugation Technology (RESPECT) utilizing a native cysteine in the light chain framework of Oryctolagus cuniculus.

Albone EF, Spidel JL, Cheng X, Park YC, Jacob S, Milinichik AZ, Vaessen B, Butler J, Kline JB, Grasso L.

Cancer Biol Ther. 2017 May 4;18(5):347-357. doi: 10.1080/15384047.2017.1312232. Epub 2017 Apr 10.

9.

Rapid high-throughput cloning and stable expression of antibodies in HEK293 cells.

Spidel JL, Vaessen B, Chan YY, Grasso L, Kline JB.

J Immunol Methods. 2016 Dec;439:50-58. doi: 10.1016/j.jim.2016.09.007. Epub 2016 Sep 24.

10.

The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity.

Lin J, Spidel JL, Maddage CJ, Rybinski KA, Kennedy RP, Krauthauser CL, Park YC, Albone EF, Jacob S, Goserud MT, Martinez BP, Chao Q, Zhou Y, Nicolaides NC, Kline JB, Grasso L.

Cancer Biol Ther. 2013 Nov;14(11):1032-8. doi: 10.4161/cbt.26106. Epub 2013 Aug 28.

12.

Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.

Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J, Chao Q, Jacob S, Turchin H, Gibbs L, Phillips MD, Mudali S, Iacobuzio-Donahue C, Jaffee EM, Moreno M, Pastan I, Sass PM, Nicolaides NC, Grasso L.

Cancer Immun. 2007 Dec 19;7:20.

13.

Developing novel biopharmaceutical products through morphogenics.

Nicolaides NC, Sass PM, Chao Q, Kline JB, Ebel W, Routhier E, Zhou Y, Grasso L.

Expert Opin Drug Discov. 2007 Dec;2(12):1619-29. doi: 10.1517/17460441.2.12.1619.

PMID:
23488905
14.

Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha.

Ebel W, Routhier EL, Foley B, Jacob S, McDonough JM, Patel RK, Turchin HA, Chao Q, Kline JB, Old LJ, Phillips MD, Nicolaides NC, Sass PM, Grasso L.

Cancer Immun. 2007 Mar 9;7:6.

15.
16.

Prolactin receptor signal transduction.

Clevenger CV, Kline JB.

Lupus. 2001;10(10):706-18. Review.

PMID:
11721697
17.

Identification and characterization of the prolactin-binding protein in human serum and milk.

Kline JB, Clevenger CV.

J Biol Chem. 2001 Jul 6;276(27):24760-6. Epub 2001 May 3.

18.
19.

Functional characterization of the intermediate isoform of the human prolactin receptor.

Kline JB, Roehrs H, Clevenger CV.

J Biol Chem. 1999 Dec 10;274(50):35461-8.

20.

Structural basis for the recognition of superantigen streptococcal pyrogenic exotoxin A (SpeA1) by MHC class II molecules and T-cell receptors.

Papageorgiou AC, Collins CM, Gutman DM, Kline JB, O'Brien SM, Tranter HS, Acharya KR.

EMBO J. 1999 Jan 4;18(1):9-21.

21.

Prolactin receptor signal transduction in cells of the immune system.

Clevenger CV, Freier DO, Kline JB.

J Endocrinol. 1998 May;157(2):187-97. Review. No abstract available.

PMID:
9659281
23.

Identification of a fibronectin-binding protein (GfbA) in pathogenic group G streptococci.

Kline JB, Xu S, Bisno AL, Collins CM.

Infect Immun. 1996 Jun;64(6):2122-9.

24.
25.

Rapid detection of group B streptococcal antigen by monoclonal antibody sandwich enzyme assay.

Morrow DL, Kline JB, Douglas SD, Polin RA.

J Clin Microbiol. 1984 Apr;19(4):457-9.

Supplemental Content

Loading ...
Support Center